# V1 Empirics Check — x-ai/grok-4.1-fast (Variant B)

**Model:** x-ai/grok-4.1-fast
**Variant:** B
**Date:** 2026-03-25T16:04:41.456243

---

### 1. Idea Fidelity
The paper faithfully pursues the core idea from the manifest: exploiting staggered transposition of the EECC (Directive 2018/1972) across EU member states as a natural experiment to estimate causal effects on consumer communications prices (Eurostat HICP CP08), using Callaway-Sant'Anna (CS-DiD) with treatment cohorts defined by transposition year (2020–2023), never-treated units (late EU transposers plus non-EU NO/CH), 2014–2024 panel data, pre-trends tests via event studies, placebo outcomes (food CP011, transport CP07, housing CP04), and secondary broadband outcomes. It fully implements the proposed identification (CS-DiD or BJS equivalent), data sources (336+ obs confirmed), and diagnostics (heterogeneity by cohort, anticipation via publication dates). No key elements are missed; the manifest anticipates administrative delays as quasi-exogenous, but the paper rigorously tests and rejects this, pivoting to a null result and methodological caution—aligning with the "smoke test" pre-trends (e.g., DK declining early, PL flat/rising).

### 2. Summary
This paper evaluates the consumer price effects of the EU Electronic Communications Code using staggered transposition timing across 27 EU states and CS-DiD on 2014–2024 Eurostat HICP communications data. It finds a precise null effect (–0.9 index points, SE=0.7), driven by violated parallel trends, significant placebo effects on unrelated prices (e.g., +8.3 on food), and cohort heterogeneity, contrasting sharply with biased TWFE estimates (–5.3 points). The contribution is twofold: a well-powered null on EECC impacts and a cautionary demonstration that EU directive transposition timing often fails as exogenous variation due to endogenous compliance linked to market conditions.

### 3. Essential Points
1. **Never-treated definition requires clarification amid post-sample treatments.** The six never-treated units include four EU states (IT, LT, PL, SK) that transposed in 2025, shortly after the 2024 sample end. While valid for in-sample identification (per Callaway-Sant'Anna with never-treated comparators), this risks contamination if 2024 prices reflect anticipation or partial implementation. Authors must provide event-study evidence excluding these four (relying solely on NO/CH) or extend data to 2025 (now feasible) to confirm robustness; otherwise, downgrade to "not-yet-treated" throughout and re-estimate ATT(g,t) dynamics.

2. **Power claims overstate null precision given assumption violations.** The minimum detectable effect (1.4 points at 80% power) assumes valid parallel trends, but pre-trends (e.g., t–6: –7.6, p<0.01) and placebos (food +8.3, p<0.01) reject this outright. Revise power discussion to emphasize that failures imply selection bias dominates, rendering the null uninterpretable as "EECC added nothing" versus "design invalid"; quantify bias via simulated violations or Sun-Abraham decomposition of TWFE weights.

3. **Endogeneity mechanism needs direct testing.** The paper attributes results to reverse causality (declining-price countries delay transposition), but provides no evidence linking pre-EECC market conditions (e.g., BEREC concentration, as manifest-proposed) to timing. Regress transposition year on 2014–2019 CP08 trends/levels (or Herfindahl indices from BEREC) with never-treated as omitted; if significant, this confirms selection and strengthens the methodological contribution.

### 4. Suggestions
The paper is coherent, data quality is excellent (balanced 319 obs panel, authoritative sources like Eurostat HICP and Commission trackers, transparent coding), and conclusions are convincingly supported by diagnostics—elevating it beyond a simple null to a methodological advance on EU policy evaluation pitfalls. To sharpen for AER:Insights, consider these enhancements:

- **Data and sample expansions (priority for external validity).** Incorporate monthly HICP data (Eurostat \texttt{prc_hicp_midx}) for finer timing, assigning treatment at gazette publication month (mitigating annual aggregation bias). Add EFTA/UK as controls post-Brexit (UK outside EECC but comparable telecom markets). Test heterogeneous effects by pre-treatment concentration: split cohorts by 2019 BEREC HHI (e.g., high vs. low) or broadband penetration (manifest-secondary outcome), estimating ATT(g) interactions—does null mask gains in concentrated markets (e.g., PL)?

- **Estimator refinements and visuals.** Report Borusyak-Jaravel-Spiess (2024) alongside CS for consistency (manifest allows either); their interaction-weighted ATT avoids CS's universal base reliance. Add \cref{fig:eventplot} (ggplot-style) for event study: overlay cohort-specific dynamics (2020 vs. 2022 divergence visually striking). Plot TWFE decomposition (Goodman-Bacon) to show negative weights from late-treated vs. early-treated comparisons driving bias.

- **Placebo and falsification deepening.** Beyond CP011/04/07, test EECC-irrelevant outcomes like Eurostat CP00 total HICP or OECD telecom revenue/share—expect nulls if selection is telecom-specific. For anticipation, interact t–1 with publication lag (gazette-to-transposition months) in event study. Sensitivity: stack pre-trends test (Rambachan-Roth) with bounds under trend deviations up to 20% of observed.

- **Institutional and welfare context.** Quantify economic magnitude: –0.9 points ≈ 0.9% of 2015=100 base (or €0.5–1bn EU-wide consumer surplus, using €500bn annual telecom spend). Discuss NRAs: merge BEREC enforcement indices post-2020; if effects zero despite stronger powers, supports "already-competitive" interpretation. Link to "bigger picture" (manifest): apply design to similar directives (e.g., PSD2 payments, 2019 stagger) for placebo ATT on CP08.

- **Presentation polish.** Expand \cref{tab:summary} with pre/post means by cohort (e.g., 2020 cohort: 2019 mean 85 vs. never-treated 102). Move robustness to main table (merge \cref{tab:main,tab:robustness}). Abstract: lead with null+methodology, not TWFE red herring. Conclusion: frame as template—"for 3,500+ EU directives, test pre-trends first."

Overall, this is publication-ready with minor fixes: strong causal focus, novel setting, and timely DiD lessons. Reject risk low; addresses manifest's "regulatory delay costs" with a rigorous no. Estimated revisions: 1–2 weeks data work, 1 week analysis.
